Buy Or Sell Opportunity • Jun 04
Now 232% overvalued after recent price rise Over the last 90 days, the stock has risen 2,800% to CA$17.40. The fair value is estimated to be CA$5.24, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 51% over the last 3 years. Earnings per share has grown by 40%. Ankündigung • May 26
Vireo Growth Inc. (CNSX:VREO) signed a letter of intent to acquire Bridgewell Agribusiness LLC from Bwab Holdings, Llc for $40.3 million. Vireo Growth Inc. (CNSX:VREO) signed a letter of intent to acquire Bridgewell Agribusiness LLC from Bwab Holdings, Llc for $40.3 million on May 25, 2026. The consideration consists of convertible debt of Vireo Growth Inc. having a value of $10.26 million to be issued for common equity of Bridgewell Agribusiness LLC. The aggregate consideration for the Bridgewell Transaction is based on a base purchase price of US$40 million, subject to adjustments for, among other things, approximately US$30 million of assumed indebtedness of Bridgewell that will remain outstanding following closing and the assumption of certain other transaction expenses. After giving effect to such adjustments, the estimated closing purchase price is expected to be approximately US$10.26 million In exchange for the issued and outstanding membership interests of Bridgewell, Vireo will issue an unsecured, subordinated convertible note to the Seller (the “Convertible Note”) in the aggregate principal amount equal to the closing purchase price, which will automatically convert on or after the second anniversary of closing into an estimated 16,552,150 subordinate voting shares of Vireo (the “Consideration Shares”) at a deemed price of US$0.62 per Consideration Share (which final price will be subject to the policies of the Canadian Securities Exchange and based on the volume weighted average trading price of the Company’s subordinate voting shares for 20 consecutive trading days ending two trading days prior to the closing date). The aggregate principal amount of the Convertible Note and number of Consideration Shares issuable thereunder are subject to certain post-closing purchase price and other adjustments.
The transaction is subject to approval by regulatory board / committee and definitive agreement. The Bridgewell Transaction could close any time following five (5) business days. Reported Earnings • May 13
First quarter 2026 earnings released: US$0.019 loss per share (vs US$0.018 loss in 1Q 2025) First quarter 2026 results: US$0.019 loss per share (further deteriorated from US$0.018 loss in 1Q 2025). Revenue: US$106.2m (up 333% from 1Q 2025). Net loss: US$20.3m (loss widened 212% from 1Q 2025). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth. Ankündigung • May 07
Vireo Growth Inc. to Report Q1, 2026 Results on May 12, 2026 Vireo Growth Inc. announced that they will report Q1, 2026 results Pre-Market on May 12, 2026 Ankündigung • May 02
Vireo Growth Inc. (CNSX:VREO) entered into a definitive arrangement agreement to acquire FLUENT Corp. (CNSX:FNT.U) for $19.2 million. Vireo Growth Inc. (CNSX:VREO) entered into a definitive arrangement agreement to acquire FLUENT Corp. (CNSX:FNT.U) for $19.2 million on April 30, 2026. As part of the acquisition, Vireo Growth Inc. will acquire all of the issued and outstanding common shares of FLUENT Corp. As part of consideration, each shareholder of FLUENT Corp will receive 0.0705359 of a subordinate voting share of Vireo Growth Inc in exchange for each FLUENT Corp Share held. Following the completion of the Transaction, FLUENT will join the Vireo ecosystem and gain exposure to a larger and well capitalized multi-state operator currently operating in 10 states across the U.S. In connection with the Transaction, Vireo has entered into voting support agreements with certain directors, officers and key shareholders of FLUENT, with such holders representing approximately 38.3% of the issued and outstanding FLUENT Shares, pursuant to which they have agreed to, among other things, vote their FLUENT Shares in favor of the Transaction. Chris Hagedorn has resigned from the FLUENT Board. The vacancy will not be filled at this time. Upon completion, it is expected that the FLUENT Shares will be delisted from the Canadian Securities Exchange (“CSE”) and the OTCQB Venture Market and that FLUENT will apply to cease to be a reporting issuer under applicable Canadian securities laws. In case of termination of transaction, FLUENT Corp. will pay a termination fee of $2 million to Vireo Growth Inc.
The transaction is subject to court approvals, as well as the receipt of all required regulatory approvals, the completion of the Equitization, and the satisfaction of certain other closing conditions customary in transactions of this nature, approval by the shareholders of FLUENT Corp and other third-party approvals. The Board of Directors of FLUENT Corp. formed a special committee for the transaction. The Special Committee and the FLUENT Board have unanimously determined that the Transaction is in the best interests of FLUENT and is fair to the FLUENT Shareholders and the FLUENT Board recommends that the FLUENT Shareholders vote in favor of the Transaction. The transaction is expected to close in the fourth quarter of 2026.
ATB Cormark Capital Markets acted as fairness opinion provider to the Special Committee and board of directors of FLUENT Corp. ATB Cormark Capital Markets acted as financial advisor to the Special Committee of FLUENT Corp. Cassels Brock & Blackwell LLP acted as legal advisor to FLUENT Corp. Goodwin Procter LLP acted as legal advisor to FLUENT Corp. DLA Piper (Canada) LLP acted as legal advisor to Vireo Growth Inc. Eversheds Sutherland (US) LLP acted as legal advisor to Vireo Growth Inc. Shenker Russo & Clark LLP acted as legal advisor to Vireo Growth Inc. Foley & Lardner LLP acted as legal advisor to Vireo Growth Inc. Ankündigung • Apr 17
Vireo Growth Inc. announced that it has received $50.612571 million in funding On April 16, 2026. Vireo Growth Inc. announced that it has closed the transaction. Ankündigung • Apr 09
Vireo Growth Inc. (CNSX : VREO) completed the acquisition of The Hawthorne Gardening Company from Smg Growing Media, Inc. for 84.6 million. Vireo Growth Inc. (CNSX : VREO) entered into a nonbinding memorandum of understanding to acquire The Hawthorne Gardening Company from Smg Growing Media, Inc. for approximately $120 million on January 15, 2026. As part of consideration Vireo Growth Inc. issued 206 million ordinary shares, a warrant to purchase 80 million at an exercise price of $0.85 per Share, exercisable for a period of five years from the date of issuance. Additional Vireo Growth Inc. acquire The Hawthorne Gardening Company $35 million of cash, approximately $50 million of net working capital, and would be provided approximately $20 million of inventory.
Vireo intends to name Chris Hagedorn, Executive Vice President of ScottsMiracle-Gro and Executive Lead of the Hawthorne business, to its Board of Directors upon completion of the transition upon completion of the transaction and shareholder approval.
The transaction is subjected to regulatory approvals and the finalization of a definitive agreement. If applicable, the approval of the Canadian Securities Exchange. The expected to be completed during the second quarter of 2026.
Vireo Growth Inc. (CNSX : VREO) completed the acquisition of The Hawthorne Gardening Company from Smg Growing Media, Inc. for 84.6 million on April 8, 2026. Under the terms of the transaction, Vireo Growth Inc. acquired $35 million of cash held by Hawthorne, and issued 213 million of its subordinate voting shares and a warrant to purchase 80 million at an exercise price of $0.85 per Share. Ankündigung • Apr 01
Vireo Growth Inc. Announces Cory Azzalino to Step into the CEO Role of Vireo’s California Business Vireo Growth Inc. announced Cory Azzalino will step into the CEO role of Vireo’s California business – Cory and his team bring operational acumen and emphasis on retail excellence which strengthens Vireo’s platform. Reported Earnings • Mar 18
Full year 2025 earnings released: US$0.093 loss per share (vs US$0.15 loss in FY 2024) Full year 2025 results: US$0.093 loss per share. Revenue: US$268.8m (up 170% from FY 2024). Net loss: US$68.1m (loss widened 143% from FY 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in Canada. Ankündigung • Mar 17
Vireo Growth Inc., Annual General Meeting, May 29, 2026 Vireo Growth Inc., Annual General Meeting, May 29, 2026. Ankündigung • Mar 10
Vireo Growth Inc. to Report Q4, 2025 Results on Mar 17, 2026 Vireo Growth Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 17, 2026 Ankündigung • Jan 28
Vireo Growth Inc. (CNSX : VREO) entered into a nonbinding Memorandum of Understanding to acquire The Hawthorne Gardening Company from Smg Growing Media, Inc. Vireo Growth Inc. (CNSX : VREO) entered into a nonbinding memorandum of understanding to acquire The Hawthorne Gardening Company from Smg Growing Media, Inc. on January 28, 2026. Upon completion, Vireo intends to name Chris Hagedorn, Executive Vice President of ScottsMiracle-Gro and Executive Lead of the Hawthorne business, to its Board of Directors. Recent Insider Transactions Derivative • Jan 02
President exercised options and sold CA$104k worth of stock On the 29th of December, Amber Shimpa exercised options to acquire 127k shares at no cost and sold these for an average price of CA$0.82 per share. This trade did not impact their existing holding. Since March 2025, Amber's direct individual holding has increased from 875.63k shares to 1.97m. This was the only transaction from an insider over the last 12 months. Ankündigung • Dec 23
Vireo Growth Inc. (CNSX:VREO) agreed to acquire Eaze Technologies, Inc. for $48.9 million. Vireo Growth Inc. (CNSX:VREO) agreed to acquire Eaze Technologies, Inc. for $48.9 million on December 22, 2025. The consideration is payable through the issuance of approximately 84 million subordinate voting shares of the Vireo at closing. Total consideration payable in the transaction will be subject to adjustment based on closing levels of cash, indebtedness, tax obligations and working capital adjustments, as well as the occurrence of certain other events by the closing date. Eaze may be entitled to earn-out consideration as of December 31, 2026. Eaze will become a wholly-owned subsidiary of Vireo.
The expected completion of the transaction is January 1, 2026 to June 30, 2026. Ankündigung • Dec 18
Vireo Growth Inc. (CNSX:VREO) entered into an asset purchase agreement to acquire Certain retail assets and properties of PharmaCann Inc. for $49 million. Vireo Growth Inc. (CNSX:VREO) entered into an asset purchase agreement to acquire Certain retail assets and properties of PharmaCann Inc. for $49 million on December 16, 2025. Total consideration is payable in subordinate voting shares of the Vireo Growth, as well as the assumption of certain liabilities.
The transaction is subject to satisfaction of closing conditions and state and local regulatory approvals. The transaction is expected to close during the first half of calendar year 2026. New Risk • Nov 14
New major risk - Revenue and earnings growth Earnings have declined by 1.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 1.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (362% increase in shares outstanding). Reported Earnings • Nov 14
Third quarter 2025 earnings released: US$0.042 loss per share (vs US$0.024 loss in 3Q 2024) Third quarter 2025 results: US$0.042 loss per share (further deteriorated from US$0.024 loss in 3Q 2024). Revenue: US$91.7m (up 264% from 3Q 2024). Net loss: US$26.3m (loss widened 434% from 3Q 2024). Revenue is forecast to grow 66% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Ankündigung • Oct 31
Vireo Growth Inc. to Report Q3, 2025 Results on Nov 12, 2025 Vireo Growth Inc. announced that they will report Q3, 2025 results After-Market on Nov 12, 2025 Ankündigung • Oct 29
Vireo Growth Inc. and Verano Holdings Corp. Reaches Comprehensive Settlement Dismissing All Outstanding Litigation Matters Vireo Growth Inc. and Verano Holdings Corp. on October 29, 2025 announced that they have reached a comprehensive settlement dismissing all outstanding litigation matters between the two Companies that are pending before the Supreme Court of British Columbia, Canada. The terms of the Settlement Agreement were approved by the respective Boards of Directors of both Companies. The value of the settlement to Vireo is approximately USD 10 million consisting of the acquisition of certain real estate assets and USD 1 million in cash. The resolution marks the conclusion of a complex legal chapter and reflects a commitment by both Companies to move forward in a constructive manner. Both Companies reiterated their dedication to delivering long-term value to their shareholders and quality products and services to their customers. Ankündigung • Oct 24
Vireo Growth Inc. announced that it has received $61.996221 million in funding On October 23, 2025, Vireo Growth Inc closed the transaction. The transaction included participation from 22 investors. Ankündigung • Sep 16
Vireo Growth Inc. Announces Launch of Adult-Use Cannabis Sales in Minnesota Vireo Growth Inc. announced that on September 16, 2025, it recorded its first sale of adult use cannabis in Minnesota at its historic downtown Minneapolis Green Goods® dispensary. The Company is now dispensing a full suite of both medical and adult-use cannabis products at all eight of its Green Goods™ dispensaries located throughout the State of Minnesota. Vireo has been operating in Minnesota’s medical cannabis market since 2014, serving tens of thousands of patients with safe, reliable products. The Company is committed to expanding access, improving product quality, and supporting the state’s transition to a sustainable, locally driven adult-use market. As one of the state’s operational licensed adult-use cannabis cultivators and retailers, and a population of 5.7 million people, the launch of Minnesota’s adult-use cannabis market is expected to serve as a strong organic revenue growth catalyst for Vireo for the foreseeable future. Green Goods® offers a full suite of medical and adult-use cannabis products and form factors including flower, pre-rolls, edibles, and beverages, and currently operates eight retail dispensaries in Minnesota. Green Goods® dispensaries are located in Minneapolis, Blaine, Bloomington, Burnsville, Duluth, Moorhead, Rochester, and Woodbury. For more information about Green Goods or to shop its product menu, please visit www.visitgreengoods.com. Reported Earnings • Aug 14
Second quarter 2025 earnings released: US$0.027 loss per share (vs US$0.005 loss in 2Q 2024) Second quarter 2025 results: US$0.027 loss per share (further deteriorated from US$0.005 loss in 2Q 2024). Revenue: US$48.1m (up 91% from 2Q 2024). Net loss: US$14.9m (loss widened US$14.3m from 2Q 2024). Revenue is forecast to grow 78% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Ankündigung • Aug 05
Vireo Growth Inc. to Report Q2, 2025 Results on Aug 13, 2025 Vireo Growth Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 13, 2025 Ankündigung • Jul 10
Vireo Growth Inc. announced that it has received $10 million in funding from Chicago Atlantic Opportunity Finance, LLC Vireo Growth Inc announced that it has completed a private placement and issued $10,000,000 principal amount of convertible Notes on July 9, 2025. The Notes are convertible into an aggregate of 16,000,000 Shares upon exercise. The new convertible note was issued in reliance upon exemptions from the registration requirements of the U.S. Securities Act of 1933, as amended and applicable Canadian and U.S state Securities laws. The transaction included participation from Chicago Atlantic Opportunity Finance, LLC. Ankündigung • Jun 10
Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Deep Roots Harvest, Inc. for $64.14 million. Vireo Growth Inc. (CNSX:VREO) has signed definitive agreement to acquire Deep Roots Harvest, Inc. on December 18, 2024. Total consideration is approximately $397 million of all-stock transactions. In Related transactions Vireo has signed definitive agreements to acquire Proper Brands in Missouri and WholesomeCo Cannabis in Utah, while also signing a binding MOU to acquire The Flowery in Florida. Vireo estimates proforma revenue and EBITDA of the combined company of approximately $394 million and $94 million, respectively, for calendar year 2024. Upon closing of the Merger Transactions, Vireo estimates the combined company will be well-positioned for further growth with a favorable balance sheet consisting of approximately $99 million of cash and $78 million of net debt with an EBITDA leverage ratio of approximately 0.8x. The Proper Brands, Deep Roots Harvest and WholesomeCo Cannabis are expected to be acquired at a multiple of 4.175x 2024 “Reference EBITDA” pro-forma for pending acquisitions as well as planned new retail openings and expansion projects. Each transaction has been based on a $0.52 Vireo share reference price. The Deep Roots Merger Agreement also contains customary indemnification obligations of Vireo and Deep Roots, other obligations of the parties and termination provisions, under which, subject to certain conditions and in certain instances of termination, would require Vireo or Deep Roots to pay a termination fee equal to $6.37624 million.
These acquisition targets may qualify for earnout payments on December 31, 2026, based on 4x EBITDA growth compared to Reference EBITDA, adjusted for incremental debt, and paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. Reference EBITDA for Proper Brands, Deep Roots Harvest and WholesomeCo Cannabis are $31.0 million, $31.0 million, and $16.0 million, respectively. John Mazarakis, co-founder at Chicago Atlantic, has been appointed to the role of Chief Executive Officer and Co-Executive Chairman, effective immediately. Tyson Macdonald, former partner at TrueRise Capital, has been appointed to the role of Chief Financial Officer, effective immediately. Amber Shimpa will continue to serve as President of the Company and as Chief Executive Officer of Minnesota, Maryland, and New York. Implementation of the Merger Transactions are subject to the approval of holders of a majority of Vireo's voting shares and regulatory approvals. The Merger Transactions have been unanimously approved by the Boards of Directors of Vireo and each of the target acquisition companies. Vireo anticipates that closing of all of the Merger Transactions to take at least six months pending shareholder and regulatory approvals. Vireo expects that each transaction will be accretive to the broader portfolio. Moelis & Company LLC acted as fairness opinion provider for Boards of Directors of Vireo Growth Inc. Moelis & Company LLC acted as financial advisor for Vireo Growth Inc. Dorsey & Whitney LLP acted as legal advisor for Vireo Growth Inc.
Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Deep Roots Harvest, Inc. for $64.14 million on June 9, 2025. Total consideration for the transaction is paid in the form of 255.2 million Subordinate Voting Shares of Vireo at a reference price per share of $0.52. The purchase price of the Deep Roots transaction represents a multiple of 4.175x 2024 “Closing EBITDA” of $30 million. Ankündigung • Jun 06
Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Proper Brands for $73.3 million. Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire Proper Brands on December 18, 2024. Under the terms of the transaction, the transaction is expected to be effected by way of an all-stock transaction, and The Proper Brands, Deep Roots Harvest and WholesomeCo Cannabis are expected to be acquired at a multiple of 4.175x 2024 “Reference EBITDA” pro-forma for pending acquisitions as well as planned new retail openings and expansion projects. Each transaction has been based on a $0.52 Vireo share reference price. Reference EBITDA for Proper Brands is $31.0 million. Vireo will include in the stock merger consideration calculation an amount equal to $2,139,200 for the stockholders of Proper Brands for all of the outstanding equity interests in Arches IP, Inc. owned by Proper Brands with a potential for earnout payments based on performance through December 31, 2026, based on the greater of $37.5 million or 5x revenue measured at the higher of trailing-twelve-month or nine-month annualized net revenues, paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. The seller of Proper Brand has agreed to voluntary share lock-up after 33 months of consummation. In separate transactions, Vireo will also acquire Deep Roots Harvest, WholesomeCo Cannabis, and The Flowery. The transaction is subject to approval by regulatory board, approval of merger agreement by target board, approval of offer by acquirer board, subject to shareholder approval and lock-up agreement, and a clawback provision if they perform below the respective Reference EBITDA measured as the higher of trailing twelve-months or nine-months annualized EBITDA as of December 31, 2026, adjusted for any intercompany funding. The Merger Transactions have been unanimously approved by the Boards of Directors of Vireo and Proper Brands. In certain instances of termination, Vireo or Proper Brands is required to pay a termination fee equal to $4,631,012.
Moelis & Company LLC acted as financial advisor and Fairness Opinion Provider, and Nicole Stanton of Dorsey & Whitney LLP acted as legal advisor to Vireo. Lineage Merchant Partners, LLC acted as placement agent for the financing.
Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Proper Brands for $73.3 million on June 5, 2025. Total consideration for the transactions was $102 million, paid in the form of 196.2 million Subordinate Voting Shares of Vireo at a reference price per share of $0.52. Ankündigung • May 13
Vireo Growth Inc. (CNSX:VREO) completed the acquisition of WholesomeCo Cannabis. Vireo Growth Inc. (CNSX:VREO) signed an agreement to acquire WholesomeCo Cannabis on December 18, 2024. Vireo has signed three definitive documents and one binding Memorandum of Understanding to acquire four single-state operators (Proper Brands, Deep Roots Harvest, and Bill’s Nursery, Inc, WholesomeCo Cannabis) for total consideration of approximately $397 million in a series of all-stock transactions and may qualify for earnout payments on December 31, 2026. Vireo will include in the stock merger consideration calculation an amount equal to $11,860,800 for the stockholders of WholesomeCo Cannabis for all of the outstanding equity interests in Arches IP, Inc. owned by WholesomeCo Cannabis with a potential for earnout payments based on performance through December 31, 2026, based on the greater of $37.5 million or 5x revenue measured at the higher of trailing-twelve-month or nine-month annualized net revenues, paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. The transaction is subject to certain shareholder and regulatory approvals, and clawback provision. In certain instances of termination, Vireo or WholesomeCo Cannabis is required to pay a termination fee equal to $3,394,217. The Merger Transactions have been unanimously approved by the Boards of Directors of Vireo and WholesomeCo Cannabis. As of March 9, 2025, Vireo Growth Inc. has obtained required regulatory approvals and is working toward satisfying all other customary closing conditions, which it expects to meet during the second quarter of 2025.
Moelis & Company LLC acted as financial advisor and fairness opinion provider, and Nicole Stanton of Dorsey & Whitney LLP acted as legal advisor to Vireo. Lineage Merchant Partners, LLC acted as placement agent for the financing. Adam Hull of Polsinelli PC acted as legal advisor to WholesomeCo.
Vireo Growth Inc. (CNSX:VREO) completed the acquisition of WholesomeCo Cannabis for $69.8 million on May 12, 2025. $69.8 million paid in the form of 134.2 million Subordinate Voting Shares of Vireo at a reference price per share of $0.52. Reported Earnings • May 10
First quarter 2025 earnings released: US$0.018 loss per share (vs US$0.047 loss in 1Q 2024) First quarter 2025 results: US$0.018 loss per share (improved from US$0.047 loss in 1Q 2024). Revenue: US$24.5m (up 1.9% from 1Q 2024). Net loss: US$6.51m (loss narrowed 3.0% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. Ankündigung • Apr 29
Vireo Growth Inc. to Report Q1, 2025 Results on May 09, 2025 Vireo Growth Inc. announced that they will report Q1, 2025 results Pre-Market on May 09, 2025 Ankündigung • Apr 09
Vireo Growth Inc., Annual General Meeting, Jun 20, 2025 Vireo Growth Inc., Annual General Meeting, Jun 20, 2025. Reported Earnings • Mar 04
Full year 2024 earnings released: US$0.15 loss per share (vs US$0.19 loss in FY 2023) Full year 2024 results: US$0.15 loss per share. Revenue: US$99.4m (up 13% from FY 2023). Net loss: US$28.0m (loss widened 9.6% from FY 2023). Revenue is forecast to grow 8.1% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Pharmaceuticals industry in Canada. Ankündigung • Feb 20
Vireo Growth Inc. to Report Q4, 2024 Results on Mar 04, 2025 Vireo Growth Inc. announced that they will report Q4, 2024 results Pre-Market on Mar 04, 2025 Ankündigung • Jan 01
Vireo Growth Inc. announced that it has received $80.960546 million in funding On December 30, 2024, Vireo Growth Inc., closed the transaction. The company issued 129,536,874 subordinate voting shares at a price of $0.625 per share for the gross proceeds of $80,960,546.25 in the transaction. The transaction has been oversubscribed. Reported Earnings • Nov 15
Third quarter 2024 earnings released: US$0.024 loss per share (vs US$0.037 loss in 3Q 2023) Third quarter 2024 results: US$0.024 loss per share (improved from US$0.037 loss in 3Q 2023). Revenue: US$25.2m (up 2.0% from 3Q 2023). Net loss: US$4.93m (loss narrowed 5.8% from 3Q 2023). Revenue is forecast to grow 3.4% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. Ankündigung • Nov 05
Vireo Growth Inc. announced that it expects to receive $10 million in funding Vireo Growth Inc. announced that it has secured a new convertible debt facility which provides a financing commitment of up to $10,000,000 in aggregate principal amount of convertible notes on November 4, 2024. This facility is being funded by the Company’s senior secured lender and its affiliates under the Company’s existing credit agreement. The convertible facility has a term of three years, with a cash interest rate of 12.0 percent, and such interest shall be paid to Lender in cash on the last business day of each calendar month. The Convertible Notes shall be convertible at any time into Subordinate Voting Shares of the Company, at the option of Lender, in whole but not in part, in a single transaction, at a conversion price equal to $0.625. Ankündigung • Oct 30
Vireo Growth Inc. to Report Q3, 2024 Results on Nov 13, 2024 Vireo Growth Inc. announced that they will report Q3, 2024 results After-Market on Nov 13, 2024 New Risk • Oct 13
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: CA$110.5m (US$80.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$23m). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (17% average weekly change). Market cap is less than US$100m (CA$110.5m market cap, or US$80.3m). Ankündigung • Oct 10
Vireo Growth Inc. Announces Resignation of Josh Rosen as Director Vireo Growth Inc. announced several leadership updates. Josh Rosen has resigned from the Company's Board of Directors, effective immediately, to focus on his other business ventures. Mr. Rosen was first elected to the Board in August 2021, and appointed to executive leadership roles in November 2022, including, most recently, the roles of Chief Executive Officer and interim Chief Financial Officer. The Company has engaged Mr. Rosen going forward with a consulting agreement. Board Change • Sep 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. CEO, Interim CFO & Director Josh Rosen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Aug 21
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 61% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$23m). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change). Ankündigung • Aug 20
Vireo Growth Inc. announced that it has received $5.3875 million in funding On August 20, 2024, Vireo Growth Inc. closed the transaction. The transaction included participation from 14 investors. Reported Earnings • Aug 07
Second quarter 2024 earnings released: US$0.005 loss per share (vs US$0.057 loss in 2Q 2023) Second quarter 2024 results: US$0.005 loss per share (improved from US$0.057 loss in 2Q 2023). Revenue: US$25.1m (up 24% from 2Q 2023). Net loss: US$668.4k (loss narrowed 91% from 2Q 2023). Revenue is expected to decline by 1.4% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in Canada are expected to grow by 11%. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. Ankündigung • Jul 23
Vireo Growth Inc. to Report Q2, 2024 Results on Aug 06, 2024 Vireo Growth Inc. announced that they will report Q2, 2024 results After-Market on Aug 06, 2024 Ankündigung • May 31
Goodness Growth Holdings, Inc. announced that it expects to receive $0.7 million in funding Goodness Growth Holdings, Inc. announced a non-brokered private placement of its subordinate voting shares for the gross proceeds of $700,000 on May 30, 2024. The company expects that this transaction will be completed within the next five business days. All of the subordinate voting shares issued in connection with this private placement will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation. Reported Earnings • May 08
First quarter 2024 earnings released: US$0.047 loss per share (vs US$0.066 loss in 1Q 2023) First quarter 2024 results: US$0.047 loss per share (improved from US$0.066 loss in 1Q 2023). Revenue: US$24.1m (up 26% from 1Q 2023). Net loss: US$6.71m (loss narrowed 20% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings. Ankündigung • May 01
Goodness Growth Holdings, Inc. to Report Q1, 2024 Results on May 07, 2024 Goodness Growth Holdings, Inc. announced that they will report Q1, 2024 results After-Market on May 07, 2024 Ankündigung • Apr 13
Goodness Growth Holdings, Inc., Annual General Meeting, Jun 21, 2024 Goodness Growth Holdings, Inc., Annual General Meeting, Jun 21, 2024. Ankündigung • Apr 03
Goodness Growth Holdings, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023 Goodness Growth Holdings, Inc. reported impairment charges for the fourth quarter ended December 31, 2023. For the period, the company reported loss on impairment of long-lived assets of USD 411,629 compared to USD 1,119,583 last year same period. Reported Earnings • Apr 02
Full year 2023 earnings released: US$0.19 loss per share (vs US$0.33 loss in FY 2022) Full year 2023 results: US$0.19 loss per share (improved from US$0.33 loss in FY 2022). Revenue: US$88.1m (up 18% from FY 2022). Net loss: US$25.5m (loss narrowed 40% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings. Ankündigung • Mar 15
Goodness Growth Holdings, Inc. to Report Q4, 2023 Results on Mar 28, 2024 Goodness Growth Holdings, Inc. announced that they will report Q4, 2023 results at 4:00 PM, US Eastern Standard Time on Mar 28, 2024 Ankündigung • Dec 15
Goodness Growth Holdings, Inc. Announces Departure of Michael Schroeder as General Counsel & Chief Compliance Officer Effective December 15, 2023 Goodness Growth Holdings, Inc. announced that the Company’s General Counsel and Chief Compliance Officer, Michael Schroeder, will depart the Company effective December 15, 2023 to accept an external opportunity at Venture Medical, LLC, a national medical devices and wound care products distributor located in Missoula, Montana. The Company plans to retain external legal counsel on an interim basis to fulfill Mr. Schroeder’s former duties as General Counsel until a permanent successor can be identified, and will continue conducting its compliance procedures through a mix of existing internal and external resources. Reported Earnings • Nov 17
Third quarter 2023 earnings released: US$0.037 loss per share (vs US$0.066 loss in 3Q 2022) Third quarter 2023 results: US$0.037 loss per share (improved from US$0.066 loss in 3Q 2022). Revenue: US$24.7m (up 31% from 3Q 2022). Net loss: US$5.23m (loss narrowed 38% from 3Q 2022). Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings. Ankündigung • Nov 03
Goodness Growth Holdings, Inc. to Report Q3, 2023 Results on Nov 14, 2023 Goodness Growth Holdings, Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023 Ankündigung • Sep 28
Goodness Growth Holdings, Inc. Announces CFO Changes Goodness Growth Holdings, Inc. announced that Chief Financial Officer, John Heller, will depart the Company effective September 30 to accept a new external opportunity. Interim Chief Executive Officer Josh Rosen will assume the additional role of Interim Chief Financial Officer. New Risk • Aug 16
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$15m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$7.9m). Earnings have declined by 17% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CA$25.4m market cap, or US$18.9m). Reported Earnings • Aug 15
Second quarter 2023 earnings released: US$0.084 loss per share (vs US$0.048 loss in 2Q 2022) Second quarter 2023 results: US$0.084 loss per share (further deteriorated from US$0.048 loss in 2Q 2022). Revenue: US$20.2m (down 4.2% from 2Q 2022). Net loss: US$7.33m (loss widened 19% from 2Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings. Ankündigung • Aug 01
Goodness Growth Holdings, Inc. to Report Q2, 2023 Results on Aug 14, 2023 Goodness Growth Holdings, Inc. announced that they will report Q2, 2023 results After-Market on Aug 14, 2023 New Risk • Jul 22
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 11% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-US$2.1m). Earnings have declined by 19% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (CA$27.8m market cap, or US$21.1m). Reported Earnings • May 17
First quarter 2023 earnings released: US$0.066 loss per share (vs US$0.11 loss in 1Q 2022) First quarter 2023 results: US$0.066 loss per share (improved from US$0.11 loss in 1Q 2022). Revenue: US$19.1m (up 22% from 1Q 2022). Net loss: US$8.41m (loss narrowed 42% from 1Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Ankündigung • May 10
Goodness Growth Holdings, Inc. to Report Q1, 2023 Results on May 15, 2023 Goodness Growth Holdings, Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 15, 2023 Price Target Changed • Jan 13
Price target decreased to CA$0.85 Down from CA$1.00, the current price target is provided by 1 analyst. New target price is 270% above last closing price of CA$0.23. The company posted a net loss per share of US$0.27 last year. Ankündigung • Dec 10
Goodness Growth Holdings, Inc. Announces Departure of Christian Gonzalez-Ocasio as Chief Operating Officer Goodness Growth Holdings, Inc. announced the departure of Chief Operating Officer, Christian Gonzalez-Ocasio. The Company intends to engage Mr. Gonzalez as a consultant for an interim period to help ensure a smooth transition with the Company's leadership team. Mr. Gonzalez had been serving as Chief Operating Officer of the Company since November 2020. He previously served as Executive Vice President of Operations, supporting manufacturing and retail initiatives, beginning in October 2019. The Company does not plan to immediately seek a replacement for the Chief Operating Officer position. Responsibilities of the position will be filled by a mix of existing internal resources. Ankündigung • Dec 06
Goodness Growth Holdings, Inc Appoints Josh Rosen to the Role of Interim President Goodness Growth Holdings, Inc. announced that it has appointed Josh Rosen to the role of Interim President, effective immediately. Mr. Rosen has been serving as a director of the Company since August 2021. While he will continue to serve on the Company's board of directors, his position as Interim President will significantly expand his roles and responsibilities. Mr. Rosen's new roles and responsibilities will focus on driving operational efficiencies and adult-use preparedness in the Company's various operating markets to better align resources to capitalize on the growing adoption of adult-use regulations and managing the Company's key capital and strategic relationships. Goodness Growth's C-Suite of executives will begin reporting directly to Mr. Rosen, effective immediately. Dr. Kyle Kingsley will continue in his role as Chairman and Chief Executive Officer, with primary responsibilities focused on collaborating with Mr. Rosen on strategy, government relations and the Company's ongoing commitment to effective medical cannabis products. Mr. Rosen and Dr. Kingsley will both report directly to the Company's Board of Directors. Mr. Rosen also serves as Managing Partner at Bengal Capital, and was formerly Chief Executive Officer and Chairman of 4Front Ventures. At 4Front, Josh helped lead the transformation of a pioneering industry consulting firm into an operations-focused, multi-state operator, notably including the acquisition of Cannex Capital. Prior to 4Front, Josh gained private equity experience managing the investment portfolio for a large family office and worked extensively in the public markets as an equity analyst, primarily at the global investment bank, Credit Suisse. Ankündigung • Nov 11
Goodness Growth Holdings, Inc. to Report Q3, 2022 Results on Nov 14, 2022 Goodness Growth Holdings, Inc. announced that they will report Q3, 2022 results After-Market on Nov 14, 2022 Ankündigung • Aug 26
Goodness Growth Holdings, Inc. Announces Launch of Boundary Waters Pre-Rolls in Minnesota Goodness Growth Holdings, Inc. announced the launch of its Boundary Waters line of premium cannabis pre-rolls focused on sustainability and environmental preservation. Inspired by Minnesota's Boundary Waters Canoe Area Wilderness, which exists within Superior National Forest, Boundary Waters pre-rolls are hand-rolled from premium whole flower and are available in Sativa, Indica and hybrid strains, and can be purchased in five-roll and ten-roll packs. The Company plans to donate a portion of proceeds from the sale of Boundary Waters products to help keep the Boundary Waters clean and safe. Boundary Waters pre-rolls come in sustainable packaging, made from 57% plant-based materials. The packages are recyclable and made to decompose at an accelerated rate in landfills, if not recycled. The pre-rolls themselves are made with biodegradable paper inserts. Boundary Waters pre-rolls are made from premium whole flower material and are available at launch in six strains, including Candy Glue, Chem Fruit Funk, Critical Jack, OG Kush, White Wedding and Flap Jacks. Boundary Waters pre-rolls are currently only available in Minnesota at Green Goods dispensaries operated by the Company's Minnesota subsidiary. Subject to regulatory approvals, the Company plans to expand the Boundary Waters brand to include additional product offerings and other markets. Reported Earnings • Aug 12
Second quarter 2022 earnings released: US$0.048 loss per share (vs US$0.044 loss in 2Q 2021) Second quarter 2022 results: US$0.048 loss per share (down from US$0.044 loss in 2Q 2021). Revenue: US$21.1m (up 48% from 2Q 2021). Net loss: US$6.18m (loss widened 13% from 2Q 2021). Over the next year, revenue is forecast to grow 96%, compared to a 61% growth forecast for the industry in Canada. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Ankündigung • Aug 12
Goodness Growth Holdings, Inc. Announces Unaudited and Condensed Impairment Results for the Quarter Ended June 30, 2022 Goodness Growth Holdings, Inc. announced unaudited and condensed impairment results for the quarter ended June 30, 2022. for the quarter, the company reported Impairment of long-lived assets of $54,739,000. Ankündigung • Aug 02
Goodness Growth Holdings, Inc. Launches Cannabis-Infused Gummies in Minnesota Goodness Growth Holdings, Inc. announced the addition of cannabis-infused gummies to its Vireo brand in Minnesota, in accordance with Minnesota's new regulations effective Aug. 1 allowing certified medical cannabis patients in the state to purchase certain edible products containing cannabis. The addition of edibles, including gummies with cannabis, into Minnesota's medical cannabis program offers an additional and sought-after delivery method for patients. Vireo's gummies are designed to meet the needs of a variety of cannabis patients. At launch, the gummies are available in 10mg THC formulations and in Key Lime, Concord Grape, Hawaiian Pineapple and Oxnard Strawberry flavors. An additional formulation, with equal amounts of THC and CBD and in Alfonso Mango flavor, is expected to follow. Vireo gummies are available in all eight of the Company's Green Goods® dispensaries in Minnesota. The launch of Vireo gummies in Minnesota comes after the Company's launch of edible gummies and chews under the HiColor™ brand in Maryland in late 2021, where it has since expanded to include seasonal flavors and new formulations, and the expansion of HiColor™ brand to the New York market in June 2022. Ankündigung • Jun 24
Goodness Growth Holdings Launches Hicolor™ Cannabis Chews in New York Goodness Growth Holdings, Inc. announced the launch of HiColor™ cannabis-infused chews in New York, which are now available through the Company's retail and wholesale channels in the New York market. The new line of cannabis-infused edibles is now available in five gourmet flavors and two formulations. HiColor™ chews were designed to meet the needs of a variety of cannabis consumers, with product offerings in 10 mg THC and 10:10 CBD:THC formulations. At launch, the chews are available to New York patients in Key Lime, Concord Grape, Hawaiian Pineapple, Oxnard Strawberry and Alfonso Mango flavors. The chews are vegan, gluten-free, Kosher, non-GMO and use only natural flavors. HiColor™ chews are currently available in all four of the Company's Vireo Health dispensaries in New York, as well as in select licensed dispensaries across the state with additional licensed dispensaries expected to add HiColor™ to their product assortment over the coming months. The New York launch of HiColor™ follows the brand's debut in Maryland in late 2021, where it continues to see great success and expanded flavor and formulation options, including seasonal flavors and a new formulation combining THC and CBN. Subject to regulatory approval, the Company plans to launch the HiColor™ brand in its Minnesota market later this year when the state's medical cannabis program expands to allow cannabis-infused edibles, expected to begin in August. Reported Earnings • May 13
First quarter 2022 earnings released: US$0.11 loss per share (vs US$0.059 loss in 1Q 2021) First quarter 2022 results: US$0.11 loss per share (down from US$0.059 loss in 1Q 2021). Revenue: US$15.6m (up 19% from 1Q 2021). Net loss: US$14.6m (loss widened 112% from 1Q 2021). Over the next year, revenue is forecast to grow 91%, compared to a 87% growth forecast for the industry in Canada. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Ankündigung • May 12
Goodness Growth Holdings, Inc. Reports Consolidated Impairment of Long-Lived Assets for the Three Months Ended March 31, 2022 Goodness Growth Holdings, Inc. reported consolidated impairment of long-lived assets for the three months ended March 31, 2022. Impairment of long-lived assets were USD 5,313,176. Price Target Changed • Apr 27
Price target increased to CA$4.00 Up from CA$3.67, the current price target is an average from 4 analysts. New target price is 100% above last closing price of CA$2.00. The company posted a net loss per share of US$0.27 last year. Reported Earnings • Mar 13
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: US$0.27 loss per share (down from US$0.23 loss in FY 2020). Revenue: US$54.4m (up 11% from FY 2020). Net loss: US$33.7m (loss widened 47% from FY 2020). Revenue missed analyst estimates by 5.9%. Over the next year, revenue is forecast to grow 88%, compared to a 76% growth forecast for the pharmaceuticals industry in Canada. 
